Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Drugs in R&D - 1 Sept 2017

Dagenais Renée, Wilby Kyle John, Elewa Hazem, Ensom Mary H H

Abstract excerpt

BACKGROUND: Genetic polymorphisms are known to influence outcomes with phenytoin yet effects in the Middle East and North Africa region are poorly understood. OBJECTIVES: The objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes in populations originating from the Middle East and North Africa region, and to characterize...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Africa, Northern
Share to Anticonvulsants
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Epilepsy

Share to Middle East

Share to Phenytoin

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28748348
DOI: 10.1007/s40268-017-0195-7
PMCID: PMC5629135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.PMID 28748348Read ↗

Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.Semantic proximity Read ↗

Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.Semantic proximity Read ↗

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.Semantic proximity Read ↗

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Semantic proximity Read ↗

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatmentSemantic proximity Read ↗

Distribution of Pharmacogenetic Polymorphisms in Ethiopians: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Pharmacogenetics of anti-seizure medications in Arab countries: a comprehensive reviewSemantic proximity Read ↗

Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.Semantic proximity Read ↗

Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.Semantic proximity Read ↗

Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.Semantic proximity Read ↗

The effect of polymorphic metabolism enzymes on serum phenytoin level.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.